B·DEBATE International Center for Scientific Debate BARCELONA

IMPPC Institut de Medicina Predictiva i Personalitzada del Càncer

CARLO M. CROCE

SPEAKER AT:

BARCELONA CONFERENCES ON EPIGENETICS AND CANCER

CHALLENGES, OPPORTUNITIES AND CANCER



November, 21st and 22nd , 2013, Barcelona

Carlo M. Croce, Professor and Chair at Department of Molecular Virology, Immunology and Medical Genetics, and Director of Human Cancer Genetics Program, Ohio State University, Columbus USA

Carlo M. Croce obtained his Medical Doctor Degree at the University La Sapienza in Rome, Italy. His research and teaching activities were mostly carried out in the United States Universities. He has been Professor in Human Genetics at the University of Pennsylvania from 1980 to 1988, Professor in General Pathology at the Temple University (1988-1991), Professor of Pediatric Medicine at the Children's Hospital of Philadelphia, and of Molecular Oncology at the Thomas Jefferson University in Philadelphia. He has served as Associate Director of the Wistar Institute of Philadelphia, as Director of the Fels Institute for Cancer Research at the Temple University as Director of the Kimmel Cancer Center, at the Jefferson University in Philadelphia and he is presently Director of the Genetics Institute at the Comprehensive Cancer Center of the Ohio State University. He was appointed Editor-in-Chief of the journal Cancer Research from 1990 to 2000. During his scientific career, he made discoveries that are considered milestones in cancer research: he was the first to demonstrate that frequent chromosomal translocations in lymphoid leukemias that bring the immunoglobulin or the T-cell receptor loci in juxtaposition to oncogenes, such as MYC, BCL1, BCL2 and TCL1, causing their oncogenic activation. He also characterized chromosomal translocations in acute leukemias that lead to oncogene activation, ABL and ALL1, through gene fusion. He also generated seminal studies in solid tumors, which took him to identify and characterize various tumor suppressor genes. His studies on FHIT are now taking him to employ this gene in anti-tumoral gene therapy clinical trials. The most recent studies led him to discover the importance of the role of microRNA in human cancer.

B·DEBATE IS AN INITIATIVE OF: biocat "la Caixa" Foundation

WITH THE COLLABORATION OF: PEBC IDIBELL CRG Centre for Genomic Regulation IRB BARCELONA ibmb CSIC